Lepu Biotech

Lepu Biopharma Co., Ltd. operates as a biopharmaceutical entity with a strategic focus on oncology therapeutics. The company was established on January 19, 2018, as a subsidiary of Lepu Medical, a manufacturer of cardiovascular interventional devices. The founder of the parent Lepu Group, Dr. Pu Zhongjie, also serves as the Chairman for Lepu Biopharma. He holds a doctorate in metal materials and founded Lepu Medical in 1999 after working in the United States.

The company's business model is centered on an integrated, end-to-end platform that spans drug discovery, clinical development, in-house GMP-compliant manufacturing, and commercialization. Revenue is primarily generated from the sale of pharmaceutical products, alongside income from licensing collaborations. A significant milestone was achieved in February 2022, when Lepu Biopharma was listed on the Main Board of the Hong Kong Stock Exchange, raising approximately US$116.1 million. The company recorded its first recurring revenues in 2022 from its drug Pucotenlimab and reported its first-ever profit in the first half of 2025.

Lepu Biopharma is dedicated to addressing unmet medical needs for cancer patients through the development of targeted therapies and immunotherapies, with a particular emphasis on antibody-drug conjugates (ADCs), oncolytic viruses, and monoclonal antibodies. Its core product pipeline includes candidates like MRG003, MRG002, HX008, and LP002. The company's ADC technology platform is a key asset, enabling the design and development of next-generation cancer treatments. Lepu Biopharma operates GMP-compliant manufacturing facilities in Beijing and is expanding its capacity with a new, larger facility in Shanghai. The company pursues a dual strategy of marketing its products through a dedicated sales force in China while also seeking international partnerships and out-licensing opportunities to maximize the global commercial value of its pipeline.

Keywords: oncology therapeutics, biopharmaceutical, antibody-drug conjugates, ADC technology, cancer treatment, immunotherapy, clinical development, targeted therapy, monoclonal antibodies, oncolytic virus, drug discovery, GMP manufacturing, Hong Kong Stock Exchange, Pucotenlimab, MRG003, pharmaceutical sales, drug licensing, clinical trials, biopharma IPO, cancer research